T he sympathetic nervous system plays a pivotal role in the regulation of myocardial function. However, hyperactivation of this pathway can cause or accelerate cardiac pathology and is inversely correlated with survival. [1] [2] [3] [4] These detrimental effects are caused by increased levels of circulating catecholamines, which act on cardiomyocytes mainly through chronic stimulation of β-adrenergic receptors (βARs). In the heart, different βAR subtypes are expressed with the β 1 and β 2 subtypes being the most abundant. 5
(PKA)-dependent signaling cascade resulting in phosphorylation of targets, such as phospholamban, ryanodine receptor 2, troponin I, and myosin-binding protein C, key regulators of cardiac function. Whereas stimulation of either β 1 AR or β 2 AR leads to a rise in cAMP accumulation, the 2 receptor subtypes exert different effects, probably because of differential cAMP subcellular compartmentation. [9] [10] [11] In fact, although β 2 AR activation endows with more protective signaling by acting against myocardial apoptosis, 7,12,13 the β 1 AR subtype has been shown to be responsible for several harmful processes occurring during the progression to heart failure. Constitutive activation of β 1 AR in vivo causes pathological cardiac hypertrophy, associated with significant fibrosis and accelerated progression toward heart failure. 14, 15 On the contrary, transgenic mice with a modest overexpression of β 2 ARs showed enhanced cardiac contractility without any deleterious effects. 16 Due to their fundamental role in regulating cardiac function, βARs are critical therapeutic targets and β 1 AR blockers have been clinically proven to be beneficial for the treatment of patients with hypertension, ischemia, postinflammatory cardiomyopathy, and heart failure. 1 MicroRNAs are small noncoding RNAs that negatively interfere with messenger RNA (mRNA) stability and translation by binding to the 3′ untranslated region of their target mRNAs. 17 The role of microRNAs under cardiac physiological and pathological conditions is well documented, and accumulating evidence corroborates their potential as novel therapeutic targets. 18 One of the most abundant microRNAs in the heart is microRNA-133 (miR-133), which has been extensively studied by us and others. [19] [20] [21] [22] In particular, its expression was found to be inversely related to cardiac hypertrophy and in human heart disease. 19 Here, we reveal miR-133 as a novel molecular player involved in the regulation of the β-adrenergic system in the heart. In particular, we demonstrate that miR-133 directly targets β 1 AR (adbr1) and several other components of the β 1 AR signaling cascade, including AC VI (adcy6), the catalytic subunit β of cAMP-dependent protein kinase A (PKA C-β, prkacb), and the exchange protein activated by cAMP (EPAC, epac). Thus, miR-133 regulates the β 1 AR pathway at multiple levels, thereby modulating cardiac function.
Methods
A detailed description of methods is provided in the Online Data Supplement.
Results

miR-133 Modulates Components of the β 1 AR Signaling Cascade
In a bioinformatic search for potential targets of miR-133, the β 1 AR (adbr1) was among the predicted target (Online Table I ). To determine whether miR-133 can directly target β 1 AR mRNA, its 3′ untranslated region was cloned into the psiCHECK-TM2 luciferase reporter vector and cotransfected with a miR-133 expressing plasmid into 293 cells. A 60% reduction in luciferase activity was found in the presence of miR-133, whereas mutation of the miR-133 target site completely abolished the repression ( Figure 1A ). Similar results were obtained using synthetic miR-133 mimics (data not shown). Further confirmation was obtained by immunoprecipitation with biotinylated miR-133 oligo on adult mouse heart homogenate following by polymerase chain reaction analysis for adrb1 mRNA on extracted total RNA ( Figure 1D ). Furthermore, in a loss-of-function experiment in neonatal cardiomyocytes (nCMs), repression of miR-133 by Ad-Decoy133 19 resulted in a ≈60% upregulation of β 1 AR protein (Online Figure I ). Taken together these results demonstrate that β 1 AR is a direct target of miR-133.
Stimulation of β 1 AR with catecholamines regulates a wide range of biological processes through the activation of intermediate signaling components, such as the second messenger cAMP and subsequently PKA. Thus, to determine whether additional regulators of the β 1 AR transduction cascade are potentially targeted by miR-133, we performed bioinformatics analysis, luciferase assays, target pull down, and miR-133 loss-of-function experiments in nCMs. Our results revealed that both AC VI (adcy6), one of the main AC isoforms expressed in cardiomyocytes, 23 and the PKA C-β (prkacb) are targeted by miR-133 (Online Table I; Figure 1B and 1D;  Online Figures I and IIA ). In addition, EPAC, an additional component of the β 1 AR signaling cascade, was also shown to be a predicted target of miR-133 (Online Table I ) and validated by luciferase and immunoprecipitation assays (Online Figure IIB and IIC).
Thus, miR-133 can directly target multiple signal transduction molecules of the β 1 AR/cAMP/PKA pathway, consistent with recent evidence that a single microRNA can target several components of the same pathway. 24, 25 
miR-133 Modulates Activation of β 1 AR Signaling in Cardiomyocytes
Based on the results described above, we sought to determine the effect of miR-133 on the activation of β 1 AR-dependent signaling using cAMP imaging in living cultured cardiomyocytes. To this aim, control and Ad-miR-133-infected cardiomyocytes were transiently transfected with the fluorescent cAMP sensor EPAC1-cAMPs and challenged by β 1 ARselective stimulation through administration of norepinephrine (10 nmol/L) in the presence of the β 2 AR-selective antagonist ICI-118,551 (100 nmol/L). As expected, this resulted in a rapid increase in cAMP levels in control cells, whereas the response was significantly reduced in miR-133 overexpressing cardiomyocytes (peak ΔR/R 0 [%]: Ad-miR-133=12.96±0.05; control=34.12±0.04; P<0.01; Figure 2A of the specificity of miR-133 in targeting β 1 AR-dependent signaling, stimulation of cardiomyocytes with the β 2 AR-selective agonist clenbuterol (10 µmol/L) caused a comparable increase in cAMP in miR-133 overexpressing and control cardiomyocytes ( Figure 2C ). In addition, no effects of miR-133 on mRNA levels of β 2 AR were found (Online Figure IIIB ). Because we found AC VI to be negatively regulated by miR-133 ( Figure 1B and 1D; Online Figures I and IIA), we next sought to determine whether miR-133 overexpression may have an effect on the ability of cardiomyocytes to synthesize cAMP in response to direct activation of ACs. We thus performed an in-cell AC activity assay by measuring the synthesis rate and maximal [cAMP] elicited by a submaximal concentration of the direct AC activator forskolin (5 µmol/L). Notably, miR-133 overexpression reduced both the maximal amount and the rate of cAMP accumulation (steady-state cAMP ΔR/R 0 [%]: Ad-miR-133=22.0±2.9; control=35.0±6.8; P<0.01; accumulation rate [dR/min]: Ad-miR-133=0.56±0.01; control=0.1±0.02, P<0.01; Figure 3A and 3B).
Based on our identification of PKA C-β as a target of miR-133 ( Figure 1C and 1D and Online Figure I ) as well as the reduced cAMP response (Figure 2A and 2B) and PKA-dependent phosphorylation of phospholamban in miR-133-overexpressing compared with control nCMs (Online Figure IIIA) , we next hypothesized that PKA activity is reduced in miR-133-overexpressing nCMs. To test this, we transfected nCMs with the fluorescent PKA activity reporter AKAR3 that allows for correlation of dynamic changes in FRET with the kinetics of PKA phosphorylation. For this purpose, we treated AKAR3-expressing nCMs with a cell-permeable cAMP analog (10 µmol/L) to activate PKA directly. As expected, the rate of PKA phosphorylation of AKAR3 was significantly lower in miR-133-overexpressing nCMs compared with control cells after the treatment with the cAMP analog (phosphorylation rate [dR/min] Ad-miR-133=1.7±0.4; control=3.6±0.4; P<0.01; Figure 3C ).
Altogether, these results demonstrate that miR-133 is directly involved in the modulation of the β 1 AR signaling pathway by acting at multiple levels downstream of β 1 AR (β 1 AR-AC VI -PKA).
miR-133 Modulates Activation of β 1 AR Signaling In Vivo
To determine whether miR-133-dependent modulation of the β 1 AR signaling pathway is taking place also in vivo, we generated an inducible cardiac-specific TetON-miR-133 inducible transgenic mouse model (Tg133) in which the pri-miR-133a-2 sequence (chromosome 2) was inserted downstream of a TetON activation system. 26 When fed with doxycycline-supplemented diet, Tg133 mice showed a 3.15and 1.65-fold overexpression of pri-miR-133a-2 and mature miR-133, respectively, while no effect was observed on the expression of endogenous pri-miR-133a-1 (chromosome 18; Figure 4A ). Consistent with the overexpression of miR-133, WHSC2, a previously validated target of miR-133, 19 was downregulated in Tg133 versus control mice (Online Figure IVB ). Furthermore, an inverse relationship between miR-133 and β 1 AR expression was confirmed in a receptordensity assay ( Figure 4B ). In agreement with results from a previous study, 21 induced Tg133 mice did not show any major phenotypic abnormalities compared with control mice as evaluated by echocardiographic analysis (data not shown). However, in agreement with our in vitro data on neonatal cells (see above), freshly isolated adult cardiomyocytes from Tg133 mice hearts showed blunted cAMP accumulation after the treatment with 100 nmol/L of the β 1 AR-selective agonist xamoterol (81.9±2 pmol/mg [cAMP/protein] versus 52.7±6 pmol/mg in control and Tg133 cardiomyocytes, respectively; Figure 4C ). Consistently, acute induction of miR-133 in Tg133 mice resulted in reduced left ventricular hemodynamic performance in response to dobutamine stimulation ( Figure 4D ). We next asked whether in a condition of chronic activation of β 1 AR signaling detrimental to cardiac performance, 27, 28 that is, during left ventricular pressure overload induced by transverse aortic constriction (TAC), induction of miR-133 expression would be sufficient to prevent alterations in cardiac function. In support of this hypothesis, Tg133 mice subjected to TAC showed preserved cardiac performance and attenuated cardiac remodeling as demonstrated by echocardiography and histological analyses (Figures 5A and 6C; Online Table III ; Online Figure IVC ). In agreement with our in vitro data, a reduction in mRNA and protein levels as well as density of β 1 AR was observed in Tg133 mice compared with control mice 1 week after TAC ( Figure 5B ; Online Figure VIB) , which was accompanied by decreased cAMP/PKA-dependent phosphorylation of phospholamban (Online Figures IVB and VIB) . At the immunohistochemical level, no difference at basal level was found (data not shown), whereas a strong reduction in apoptosis To evaluate how the observed cardioprotection in Tg133 mice relates to that mediated by pharmacological blockade of β 1 signaling, C57J/B6 mice were subjected to TAC, whereafter half received treatment with a clinically relevant dose of metoprolol (350 mg/kg/d). Echocardiographic analysis revealed a reduction in the TAC-induced decrease in fractional shortening in metoprolol-treated mice (Online Figure VA) to an extent that is comparable to or lower than that observed in Tg133 mice. Furthermore, metoprolol administration prevented the expected downregulation of miR-133 1 week post TAC and maintained miR-133 at levels comparable to those of the sham group ( Figure 5C ). On the contrary, no significant differences in miR-133 levels between metoprolol-treated and untreated mice were found 3 weeks after TAC.
Altogether, these data show that miR-133 modulates the β 1 AR transduction axis both in vitro and in vivo and suggest that the partial protective effect of β-blockers might be due to the preservation of miR-133 expression levels during the first phase of pressure overload, which is the time frame when miR-133 expression is decreased.
miR-133 Protects Cardiomyocytes From β 1 AR-Induced Apoptosis In Vitro and In Vivo
Because prolonged stimulation of cardiomyocytes with β 1 AR has previously been shown to be associated with activation of apoptotic cell death, [29] [30] [31] [32] we hypothesized that miR-133 overexpression affects nCM susceptibility to apoptosis in response to chronic βAR activation. To determine this, we stimulated Ad-miR-133-infected and control nCMs with different doses of norepinephrine in the presence of the β 2 AR antagonist ICI-118,551. Immunostaining for the apoptotic marker caspase-3 after 72 hours of treatment revealed a significant reduction in the fraction of caspase-3-positive nCMs in norepinephrinetreated miR-133 overexpressing nCMs compared with control cells ( Figure 6A ; Online Figure VIIA) , indicating that miR-133 overexpression protects nCMs from β 1 AR-induced apoptosis. Conversely, miR-133 downregulation, as obtained by infection with Ad-Decoy133, resulted in a significant increase in nCM apoptosis ( Figure 6B ), accompanied by a considerable Figure VIIB) . In agreement with our in vitro data, the fraction of apoptotic myocardial cells was significantly lower in Tg133 mice compared with control mice both 1 and 3 weeks after TAC ( Figure 6C ; Online Figure VB ). This was accompanied by reduced fibrosis and resulted in cardioprotection in Tg133 mice ( Figure 6C ). In line with this, Tg133 mice at 1 week after TAC showed reduced levels of the β 1 but not β 2 -adrenergic receptor kinase (G protein-coupled receptor kinases 2 and 3, respectively; Figure 6D ; Online Figure  IVD ), which has previously been shown to exert a prodeath function. 33 Likewise, also the mRNA levels of identified miR-133 targets were downregulated in Tg133 mice after TAC ( Figure 5B ; Online Figure VIA) .
Taken together, these data demonstrate that by targeting multiple components of the β 1 AR-signaling cascade, miR-133 protects cardiomyocytes from β 1 AR-induced apoptosis.
Discussion
In this study, we provide the first evidence that miR-133 controls the β 1 AR system at multiple levels along its signaling axis in cardiomyocytes. In particular, we show that miR-133, by targeting the β 1 -receptor itself and its downstream effectors AC VI and PKA C-β, is a key modulator of the β 1 AR-mediated accumulation of the second messenger cAMP (Figure 7 ). This result is in line with a growing body of evidence demonstrating that microRNAs play a role in modulating specific receptor pathways in cardiomyocytes. 24, 25 For example miR-1, which together with miR-133 is one of the most highly expressed microRNAs in the heart and is transcribed from the same bicistronic unit as miR-133, was found by us and others to regulate the insulin-like growth factor 1/insulin-like growth factor 1 receptor signal transduction pathway, 25, 34 a key regulator of cardiac muscle trophism and function. Recent studies have demonstrated a role of βAR signaling in controlling microRNA expression. For instance, a group of 18 microRNAs was reported to be differentially expressed in the heart in response to βAR agonist or antagonist treatment. 35 Similarly, Kim et al 36 recently showed altered expression levels of a number of microRNAs in response to treatment with the β-arrestin 1-biased βAR agonist carvedilol. In another study, β-blockers were found to induce serum responsive factor -mediated inhibition of miR-1 expression, which appeared to be correlated with PKA-dependent phosphorylation of serum responsive factor in response to βAR activation. 37 These data correlate with a study on patients with chronic heart failure, where altered microRNA expression was found to be associated with reduced catecholamine sensitivity. 38 Finally, the microRNA let-7f was found to target β 2 AR directly and to be negatively regulated by β 2 -agonist stimulation. 39 However, a direct link between microRNAs and the β 1 AR cascade has not previously been demonstrated.
Our data show that miR-133 specifically interferes with the β 1 AR signaling pathway and excludes any potential effect of the microRNA on β 2 AR signaling. In fact, no effect on the cAMP accumulation rate was observed in miR-133overexpressing cardiomyocytes treated with β 2 AR-selective agonist. The miR-133 targeting of AC VI , which has been found to be selectively coupled to β 1 AR, further supports its pathway specificity for the β 1 axis. On the contrary, adenylate cyclase V, which is not a miR-133-predicted target, is predominantly associated with activation of β 2 AR signaling. 40 Thus, miR-133 overexpression in cardiomyocytes should change the balance between β 1 -and β 2 -dependent effects toward the β 2 ARdependent signaling pathway, resulting in cardioprotection and counteraction of deleterious effects due to activation of the β 1 AR. Apoptosis is among the detrimental processes that are triggered by β 1 AR activation, consistent with the reported antiapoptotic role of miR-133. 21 In agreement with this, both our in vitro and in vivo data ( Figure 6) show that miR-133 protects cardiomyocytes against β 1 AR-induced apoptosis. Furthermore, mRNA levels of grk2, which is upregulated in heart failure exerting a prodeath function, 33 were downregulated in Tg133 mice 1 week after TAC ( Figure 6D ). On the contrary, no differences were found in mRNA levels of grk3, which is mainly associated with endothelin receptors. 41 In this study, we also demonstrated that miR-133 targets EPAC (Online Figure IIB and IIC) , which is involved in the modulation of cAMP levels through a negative feedback loop between the cAMP-specific phosphodiesterase 4D3 and PKA. 42 Thus, the decreased cAMP levels in response to miR-133 overexpression may be not only due to downregulation of the miR-133 targets β 1 AR, AC VI , and PKA C-β but also due to enhanced phosphodiesterase 4D3 activity consequent to EPAC downregulation. Furthermore, EPAC has been shown to be associated with Ca 2+ /calmodulin kinase II and βarrestin at the β 1 AR, [43] [44] [45] suggesting that by targeting EPAC, miR-133 affects the Ca 2+ /calmodulin kinase II-dependent signaling in the failing heart. Future studies are needed to shed more light on this matter.
Previous studies on transgenic mice constitutively overexpressing miR-133 have shown major discrepancies, most likely owing to the different approaches used. In fact, whereas miR-133 overexpression driven by an early embryonic promoter (β-myosin heavy chain) caused a lethal phenotype with detrimental cardiac defects in survivors to adulthood, 20 a normal basal cardiac phenotype was obtained when transgenic miR-133 was stably overexpressed at a later postdevelopmental phase under the control of the α-myosin heavy chain promoter. 21 In agreement with the latter study, our echocardiographic analysis on induced adult Tg133 mice showed no abnormalities under basal resting conditions compared with control mice, although a reduction in fractional shortening was observed with extended time of microRNA induction (Online Figure IVC) . On the other hand, whereas the α-myosin heavy chain-transgenic mouse model showed impaired cardiac performance in response to ventricular pressure overload, our inducible miR-133 transgenic mice exhibited preserved fractional shortening and attenuated cardiac remodeling ( Figures 5 and 6 ). These apparently contrasting results might be due to the different modalities of miR-133 expression and possibly to compensatory mechanisms that might be activated when miR-133 is constitutively overexpressed.
Conclusions
In this study, we demonstrate with several complementary approaches that miR-133 targets distinct components of the β 1 AR pathway and provide evidence suggesting that restoration of miR-133 levels in patients might be used as a potential novel therapeutic strategy for the treatment of cardiovascular diseases. This is in line with our observation that downregulation of miR-133 levels in condition of pressure overload can be counteracted by administration of a clinically relevant βblocker. Current therapeutic strategies are mainly designed to achieve inhibition of endogenous levels of specific microR-NAs in vivo through the use of microRNA-antisense oligos. 18 For example, downregulation of various microRNAs have been shown to have beneficial effect on cardiac fibrosis and remodeling, [46] [47] [48] regeneration, 49 and neoangiogenesis. 50 As of yet, overexpression of microRNAs in vivo has only been achieved through the use of viral vectors, 51 which as opposed to antisense technology, do not allow for transient microRNA modulation. Thus, the development of improved strategies for efficient and specific expression of microRNAs in the heart is needed before microRNA replacement can be envisioned as a therapeutic strategy.
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